NewAmsterdam Pharma Company N.V. (NAMS) vs Precigen, Inc. (PGEN)
- NewAmsterdam Pharma Company N.V. NAMS 19.83 −3.83%
- Precigen, Inc. PGEN 6.35 −11.81%
NewAmsterdam Pharma Company N.V. and Precigen, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Precigen, Inc. are of similar size ($2.6B and $2.5B). Precigen, Inc. grew revenue faster over the last twelve months: 1,875.1% against −88.9%. Precigen, Inc. has the higher net margin (−392.8% vs −3,644.2%) and the lower return on invested capital (−24.9% vs 0.00%). Across the 17 metrics below, NewAmsterdam Pharma Company N.V. leads on 9 and Precigen, Inc. on 8.
Valuation
Profitability
| Metric | NAMS | PGEN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 90.67% | 65.16% |
| Operating margin | (3,432.20%) | (46.08%) | 0.00% |
| Net margin | (3,644.21%) | (392.81%) | 0.00% |
| Free cash flow margin | (2,018.28%) | (134.42%) | 0.00% |
| Return on equity | (36.81%) | (9,907.46%) | (56.36%) |
| Return on assets | (34.16%) | (247.40%) | (48.04%) |
| Return on invested capital | 0.00% | (24.87%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack